[ad_1]
\n<\/p>\n
The AbbVie Durham campus, which will be located near Research Triangle Park<\/span><\/span>, is part of the drugmaker\u2019s broader $100 billion commitment<\/a> to U.S. research and development, as well as manufacturing, over the next decade.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n The first phase of construction will include small-volume parenteral drug manufacturing facilities, laboratories, a warehouse, administrative offices and employee wellness centers, according to a news release. SVPs are sterile, injectable pharmaceutical products such as vials, prefilled cartridges and prefilled syringes containing medicines for injections or infusions. They are typically less than 100 milliliters by volume.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n Once construction is complete, AbbVie said the Durham campus will be its U.S. center of excellence for SVP manufacturing with the ability to deliver medicines to patients worldwide. AbbVie chose the site for its ability to support future expansion and its proximity to the area\u2019s strong local workforce.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n \u201cBy establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina,\u201d Robert Michael, AbbVie chairman and CEO, said in a statement.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n The state recently approved a <\/span><\/span><\/span><\/span><\/span><\/span>job development investment grant<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> that would reimburse AbbVie up to $19.3 million for its project over 12 years. The payments will begin only after the state is able to measure and verify that AbbVie has met its incremental job creation and investment targets, according to the office of North Carolina Gov. Josh Stein.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n As part of the grant agreement, the state said it will also move as much as $6.4 million into its industrial development fund utility account, which is designed to support infrastructure upgrades in rural areas to attract future businesses. AbbVie\u2019s project is estimated to add $8 billion to the state\u2019s economy.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n AbbVie has pledged to invest more than $2.2 billion in U.S. manufacturing over the past year, creating jobs in North Carolina, <\/span><\/span><\/span><\/span><\/span><\/span>Illinois<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a>, Arizona and Massachusetts. This adds to the growing number of drugmakers spending billions expanding their manufacturing and R&D in the United States to better reach domestic customers amid tariffs and geopolitical disruptions.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n CSL Behring <\/span><\/span><\/span><\/span><\/span><\/span>broke ground<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> on a $1.5 billion immunoglobulin plant in Kankakee, Illinois, last month. Earlier this year, Pennsylvania secured <\/span><\/span><\/span><\/span><\/span><\/span>more than $1 billion<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> from Johnson & Johnson and <\/span><\/span><\/span><\/span><\/span><\/span>$3.5 billion from Eli Lilly<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> to build drugmaking facilities focused on cancer and weight-loss medications, respectively.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<\/p><\/div>\n